



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

L-Arginine-d₇ hydrochloride

| | |
|---------------------------|--|
| Cat. No.: | HY-N0455AS2 |
| CAS No.: | 204244-77-9 |
| Molecular Formula: | C ₆ H ₈ D ₇ ClN ₄ O ₂ |
| Molecular Weight: | 217.71 |
| Target: | NO Synthase; Endogenous Metabolite |
| Pathway: | Immunology/Inflammation; Metabolic Enzyme/Protease |
| Storage: | -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



SOLVENT & SOLUBILITY

In Vitro

H₂O : 250 mg/mL (1148.32 mM; Need ultrasonic)

| Concentration | Mass | | | |
|---------------|-----------|------------|------------|--|
| | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5933 mL | 22.9663 mL | 45.9327 mL | |
| 5 mM | 0.9187 mL | 4.5933 mL | 9.1865 mL | |
| 10 mM | 0.4593 mL | 2.2966 mL | 4.5933 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

L-Arginine-d₇ (hydrochloride) is the deuterium labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA